Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04687020 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 2031 to Sep 2032 Trial status: Enrolling by Invitation to Active, Not Recruiting · Enrollment target: estimated 16 to confirmed 9 · Study sites: 3 to 5 · 1 morev5 Show 4 more changesShow less
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: estimated 16 to confirmed 9
    • Study sites: 3 to 5
    • Completion date: Nov 2031 to Oct 2032
  2. Primary endpoints: 4 to 5 Trial status: Recruiting to Enrolling by Invitation · Study sites: 1 to 3v4 Show 2 more changesShow less
    • Trial status: Recruiting to Enrolling by Invitation
    • Study sites: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of May 2021 to Jun 10, 2021v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2021 to Jun 10, 2021
  4. Start date: Feb 2021 to May 2021 Primary endpoints revised (4)v2 Show 1 more changeShow less
    • Primary endpoints revised (4)

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.
Trial Details
NCT Number NCT04687020
Lead Sponsor NS Pharma, Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov